20:55 , Apr 11, 2019 |  BC Week In Review  |  Company News

WuXi Biologics to manufacture NBE’s ADC for clinical trials

WuXi Biologics will manufacture NBE-Therapeutics’ lead antibody-drug conjugate, NBE-002, for use in clinical trials worldwide. NBE-Therapeutics AG (Basel, Switzerland) plans to begin trials of the ADC in mid-2020. NBE-Therapeutics declined to disclose details. WuXi Biologics...
23:51 , Mar 14, 2019 |  BC Week In Review  |  Company News

GTx and Oncternal merging

GTx and Oncternal will merge to create a company focused on developing cancer therapies. Oncternal Therapeutics Inc. (San Diego, Calif.) will hold about 75% of the combined company, which will trade on NASDAQ under the...
18:23 , May 23, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Breast cancer; brain cancer; solid tumors Mouse studies suggest liposomal nanoparticles loaded with immunomodulatory agents could enhance the efficacy of CAR T therapies to treat solid cancers. The liposomal nanoparticles are coated with an...
21:06 , May 16, 2018 |  BC Extra  |  Preclinical News

Nanoparticle pretreatment could boost solid tumor CAR T therapy

Research from the University of Washington and the Fred Hutchinson Cancer Research Center suggests preconditioning cancer patients with immunomodulatory nanoparticles could increase the efficacy of CAR T therapies to treat solid tumors. The main hypothesis...
22:06 , May 11, 2017 |  BC Innovations  |  Tools & Techniques

Stemming the tide

OncoMed’s bad April has all the hallmarks of a death knell for the once-promising technology of cancer stem cells, adding to the pile of preclinical breakthroughs that didn’t translate to the clinic. But many insiders...
18:47 , Mar 17, 2017 |  BioCentury  |  Emerging Company Profile

B-ing persistent

Aleta Biotherapeutics Inc. is extending the use of CD19 -targeting CAR T cells by coating non-B cell tumors with the antigen. President and CSO Paul Rennert told BioCentury the key to effective CAR T cell...
18:16 , Feb 2, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Breast cancer Cell culture and mouse studies suggest inhibiting ROR1 or the long non-coding RNA (lncRNA) MAYA could help treat bone-metastatic breast cancer. In a bone-metastatic human breast cancer line, ROR1 knockout or MAYA...
07:00 , Oct 24, 2016 |  BioCentury  |  Emerging Company Profile

RORing against resistance

  Oncternal Therapeutics Inc.’s ROR1 inhibitor could be combined with BTK inhibitors to increase response rates in chemotherapy-resistant or refractory hematologic cancers such as chronic lymphocytic leukemia and mantle cell lymphoma. The Bruton’s tyrosine kinase...
07:00 , Jul 28, 2016 |  BC Innovations  |  Tools & Techniques

Innate harmony

On the heels of cancer immunotherapy's clinical success, NK cells - a long-known but underappreciated component of the innate immune system - are emerging as the hottest new tool to fight cancer, with the potential...
07:00 , Jul 18, 2016 |  BioCentury  |  Product Development

ROCKET resumes

The swift release of a clinical hold on Juno Therapeutics Inc .'s ROCKET trial notwithstanding, why and how high-dose fludarabine contributed to fatal neurotoxicity remains an unanswered - and important - question for the CAR...